SSCJC: Real World Depression Measurement

An SSC Journal Club analysis of the PANDA trial (the largest non-pharma antidepressant RCT: sertraline vs placebo in 655 'real-world' primary-care patients with genuine uncertainty about whether they'd benefit). Scott converts the endpoints to a clean effect-size table (all small to low-medium; highest 0.49 on patient-rated improvement), and uses it to address the long-standing puzzle of why antidepressant RCTs undersell what doctors/patients report — antidepressants do better on vague/global symptoms and patient self-report than on researcher-measured specific symptoms (matching Hieronymus et al). Reframes 'clinically insignificant' as converting ~30% of nonresponders to responders.

Quality 64 · Strong. 64 — low Strong. A clear, useful single-study analysis with genuine clinical insight (the patient-report vs researcher-measure discrepancy) and characteristic stats exposition, but in-the-weeds and bounded to one trial. Firm low-Strong.

Claude’s paradigm shift 46 · Moderate. 46 — Moderate. A single-trial review with a useful interpretive frame; not novel.

Real-world impact 2 · Minor. 2 — minor/within-blog. Niche psychiatry analysis; no material reach.